awmsg logo

eribulin mesilate (Halaven®)

Reference No. 1212

Publication date:

Appraisal information

eribulin mesilate (Halaven®) 0.44 mg/ml solution for injection

Company: Eisai Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 16/03/2016
AWMSG meeting date: 20/04/2016
Submission Type: Full Submission
Status: Superseded
Advice No: 0916
Ratification by Welsh Government: 29/04/2016

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA423) NICE GUIDANCE ISSUED DECEMBER 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Eribulin mesilate (Halaven®) is licensed for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Eribulin mesilate (Halaven®) is recommended as an option for restricted use within NHS Wales after at least two prior chemotherapeutic regimens for advanced disease which includes capecitabine. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Eribulin mesilate (Halaven®) is not recommended for use within NHS Wales outside of these circumstances.
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary
Final Appraisal Recommendation (FAR)